Disco <6146>: 37,980 yen (+2,400 yen)

Rebound. The company announced its second quarter financial results the previous day. The operating profit for the period of July to September was 42.6 billion yen, a 51.6% increase year-on-year, exceeding the level estimated from the individual revenue report released on October 4. The improvement in gross profit margin has been better than expected, leading to positive evaluation factors for the stock price. On the other hand, the forecast for the period from October to December is 29.2 billion yen, which is about 15 billion yen below market expectations, but it is still considered conservative as usual.

Meiko <6787>: 6,160 yen (+380 yen)

Sharp rise. Morgan Stanley MUFG Securities has newly rated the investment as 'overweight' with a target stock price set at 7,600 yen. The shift away from China in the supply chain and the expansion of demand for in-vehicle printed circuit boards in the two PCB markets are seen as tailwinds. It seems that under a clear vision capturing the market trends, the results of proactive investments made towards expanding production capacity are beginning to emerge.

Nippon Shokuden <6849>: 2,283 yen (+203.5 yen)

Sharp rise. The company announced a revision to its earnings forecast the previous day. The first half operating profit has been upwardly revised from the previous estimate of 3 billion yen to 5 billion yen, a 33.3% decrease year-on-year, while the net profit has been downwardly revised from 1.5 billion yen to 0.5 billion yen. Due to strong sales of AEDs in the PAD market, domestic sales have been exceeding expectations. On the other hand, due to the recognition of foreign exchange losses, the ordinary profit and below has been revised downward. As the first quarter was an operating loss, there is a preemptive move to view the rapid recovery based on core business positively.

Sansan <4443>: 2,387 yen (+212 yen)

Marked rise. At Nomura Securities, the investment rating has been upgraded from 'Neutral' to 'Buy', and the target stock price has also been raised from 2,500 yen to 2,700 yen. Despite the softening of the stock price due to weak operating profits in the first quarter, the fundamentals indicated by adjusted operating profits etc. are strong, and the earnings forecast has been revised upwards mainly due to the improvement in gross profit margin. It is expected that the company will achieve operating profit in the second quarter and the stock price seems to be entering a phase that incorporates medium to long-term growth potential.

Kasumigaseki Capital <3498>: 14,320 yen (-1,780 yen)

Significant drop. It has announced the issuance of Euro-yen CBs maturing in 2029. The total amount of bonds is 22 billion yen, with a conversion price set at 17,710 yen, resulting in an increase rate of 10.00% over the previous day's closing price. The allotment date for the subscription rights is November 5th, with the exercise period from November 19th to October 22, 29 years. The potential dilution rate through this financing is 12.63%, which seems to be a negative factor for selling. The raised funds are primarily for land acquisition funds for development, development funds, and property acquisition funds.

Body Note <4014>: 524 yen (+3 yen)

Rebound. After the trading on the 17th, it announced medium-term management plans, business plans, and growth prospects, which have been well received. Aiming for a revenue of over 5 billion yen for the fiscal year ending in July 28 (actual result for the year ending in July 24 was 2.19 billion yen), an operating profit of over 1.5 billion yen (compared to 0.1 billion yen) with an operating profit margin target of 30% (compared to 4.6%). Considering the impact of measures like M&A cancellation, it is reviewing its strategy, postponing the planned restructuring for one year, striving to meet the listing standards of the Tokyo Stock Exchange Prime Market for business value expansion.

Nifty Life <4262>: 867 yen (+10 yen)

Rebound. It has announced the start of collaboration between its Data Feed Optimization service "DFO" and NTT Docomo's new online shopping service "d Point Market," which is viewed positively as good news. With the collaboration starting, creating and posting product data feeds for "d Point Market" has become easier and smoother, allowing for efficient operation. Furthermore, by using their "DFO" service, internal adjustments, system development, and other tasks related to creating and operating data feeds in-house become unnecessary, leading to reduced workload, cost savings, and shortened implementation periods.

DWTI <4576>: 73 yen (+2 yen)

Surge. It has announced the signing of a joint research agreement with the University of Tokyo for the purpose of research and development of a new therapeutic drug related to glaucoma surgery. The primary treatment for glaucoma involves administering eye drops, but if eye drops are ineffective depending on the progression, laser treatment or glaucoma surgery may be necessary. Glaucoma surgery not only carries the risk of serious postoperative complications but also may not have sufficient efficacy. The company, along with Tokyo University's Quantitative Life Sciences Research Institute's Special Contract Professor Atsushi Miyajima and Professor Kazuhiro Aihara from the Graduate School of Medicine's Ophthalmology Department, will conduct joint research aiming to develop a groundbreaking new eye drop for glaucoma surgery.